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Engineer the enzyme’s 
nano-environment
Empowering enzymes
the enzzen® platform: a soft protection layer
Patent WO2015014888
Enzymes made resistant











Tuning the layer thickness, its 
composition, its porosity
Co-immobilizing cocktails of enzymes
Possibly built on a magnetic core
Directed binding with specific tags












6 different digestion enzymes
No self-digestion
Resistance to chaotropic conditions
Unpolluted AA spectra
Quantitative release of a biomarker
enzzen® FOR BIOCONJUGATION
Sortase-mediated bioconjugation
No enzyme in the final product
Tuning the layer thickness for large 
substrate accessibility
Avoid Ab binding




Tuning the layer composition
Up to 360 fold increased yield
Glucosidase, transaminase, lipase, 
etc.
enzzen® FOR BIOSAFETY
Adapted with large particles, 
formulation material
Absence of immunogenicity measured 
with anti-Enz Ab
Less than 0.1% leachate of the enzyme
INOFEA AG founded in 2014
Located in Basel, Switzerland
5 employees
Privately funded
Addressing the Health Industry
Manufacturing at CMO in Switzerland
5 major customers
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